Pfizer Inc
NYSE: PFE
$28.46
-$0.40 (-1.4%)
Closing Price on October 29, 2024
PFE Articles
The most shorted stock traded on the New York Stock Exchange — Chesapeake Energy — bucked the short interest trend with a modest gain in February.
Published:
Last Updated:
Pfizer has announced that the FDA approved Xeljanz XR (tofacitinib citrate) extended-release tablets for the once-daily treatment of moderate to severe rheumatoid arthritis in certain patients.
Published:
Last Updated:
These stocks make good sense for long-term patient investors that have a growth and income total return bias in their portfolios.
Published:
Last Updated:
In a new research report, Jefferies shuffles some of the pharmaceutical stocks in its coverage universe and a beaten-down dividend leader is now the top pick globally.
Published:
Last Updated:
For worried investors that need an income stream, all these top stocks make good sense for growth and income portfolios.
Published:
Last Updated:
Pfizer has announced that it had settled outstanding claims for a total of more than $784 million related to calculated Medicaid rebates for the drug Protonix.
Published:
Last Updated:
Here are six biotech and pharma stocks that analysts are telling their firm's clients to buy now for solid upside opportunities ahead.
Published:
Last Updated:
The January 29 short interest data have been compared with the previous figures, and for the selected pharmaceutical stocks short interest increased.
Published:
Last Updated:
Among the six most heavily shorted stocks traded on the New York Stock Exchange, short sellers continued to pile on Alcoa and Freeport-McMoRan between the January 15 and January 29 settlement dates.
Published:
Last Updated:
Merrill Lynch has decided to add Pfizer as its new top pick for 2016. The firm reiterated a Buy rating with a $39 price target.
Published:
Last Updated:
The top analyst upgrades, downgrades and initiations seen on Tuesday include Apple, Freeport-McMoRan, Kinross Gold, Pfizer, Plains All American, Salesforce,com, Tesla and Yelp.
Published:
Last Updated:
If you ever want to look for value in a sector in the stock market, then when you see Congress calling in some of the top companies to scold them for political purposes, you may want to start buying.
Published:
Last Updated:
After Pfizer and Merck released their most recent earnings reports last week, analysts weighed in on both of these pharmaceutical giants.
Published:
Last Updated:
Needless to say, the stock market can be a very cruel mistress. So what are patient long-term investors to do?
Published:
Last Updated:
Pfizer reported better-than-expected fourth-quarter and full-year 2015 results before markets opened Tuesday morning.
Published:
Last Updated: